ResearcherSecond Affiliated Hospital of Nanchang UniversityNo recent work listed
Lin Zhong
Matched on ORCID iD 0009-0004-5068-3943; OpenAlex author ID A5100743869. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 3
2018: 2 papers · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper
Papers 3
- FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2. Co-author DOI 10.1007/s10620-022-07780-6↗
- Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer. Last author DOI 10.1016/j.msec.2018.04.011↗
- Corrigendum to "Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer" [Mater. Sci. En… Last author DOI 10.1016/j.msec.2018.05.067↗
Closest collaborators
The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Wentao Yang · 3 shared papers, 2018–2023 · strength 0.42
- Paper FBXO22 Accelerates Pancreatic Cancer Growth by Deactivation of the Hippo Pathway via Destabilizing LATS2. DOI 10.1007/s10620-022-07780-6↗
- Paper Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic… DOI 10.1016/j.msec.2018.04.011↗
- Paper Corrigendum to "Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic effica… DOI 10.1016/j.msec.2018.05.067↗
- Jingsheng Ma · 1 shared paper, 2023 · strength 0.20
- Lu Fang · 1 shared paper, 2023 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.